Panitumumab
CAS No. 339177-26-3
Panitumumab ( —— )
Catalog No. M22158 CAS No. 339177-26-3
Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 484 | In Stock |
|
10MG | 691 | In Stock |
|
25MG | 1035 | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePanitumumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionPanitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
-
DescriptionPanitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number339177-26-3
-
Formula Weight147 kDa
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Cohenuram M, et al.Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs. 2007 Jan;18(1):7-15.
molnova catalog
related products
-
CHMFL-EGFR-202
CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).
-
Monastrol(b)
Monastrol is a potent and cell-permeable inhibitor of the mitotic kinesin Eg5.
-
Befotertinib
Befotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.